tbuckley/cabot-search huggingface dataset:
The blight and the plight
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hashish
Authors: Michael R. McKee
Journal: JAMA (1971)

<h3>To the Editor.—</h3> Regarding the "Hashish" article by Tennant et al (<b>216</b>:1965, 1971), there is no reason for their almost-apologetic statement that the substance they studied was illegal and therefore probably contaminated. Quite the opposite; rather than the methodologically more sophisticated but often substantively more sterile conclusions that are currently appearing from some authors who have used the synthetically produced and pure drugs, we need far more studies of just this type. Far too little is known about the common "street" drugs which are currently being used and abused. We need more work done on what is the usual, normally consumed substance, and that material is quite certainly going to be impure and contaminated. Tennant et al might have been more cautious about some of their general statements, due to the size of their sample. With only 31 subjects, it is difficult to draw statistically significant conclusions. A follow-up of their
Heterogeneity in older acute myocardial infarction patients: The importance of age Rajendra H. Mehta, Saif S. Rathore, Martha J. Radford, Alan K. Berger, Yongfei Wang, Harlan Krumholz. Yale University School of Medicine, New Haven, CT, Qualidigm, Middletown, CT
Journal: Journal of the American College of Cardiology (2001)
Foot Orthopaedics.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Community empowerment as a strategy for health promotion for black and other minority populations
Authors: R. L. Braithwaite
Journal: JAMA (1989)

THE HEALTH status of blacks, other minorities, and the poor remains unconscionably low when contrasted with that of white Americans. This disparity is not new but is an historical trend that can be seen across all categories of the leading causes of death and disease. In August 1985, the<i>Report of the Secretary's Task Force on Black and Minority Health</i><sup>2</sup>noted that minorities experienced approximately 60 000 "excess deaths" annually. Margaret Heckler, who was then the secretary of the US Department of Health and Human Services, emphasized that the disparity is "an affront both to our ideals and to the ongoing genius of American Medicine." The six major contributors to the disparity between black and white death rates are cancer, cardiovascular disease and stroke, diabetes, chemical dependency, homicide and accidents, and infant mortality. Since the 1985 report, blacks and Latinos, in particular, also have evidenced a disproportionately high rate
American Journal of Medical Sciences, Philadelphia
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NHS review
Authors: S. Jenkins
Journal: BMJ (1989)

<h3>Background</h3> Novel Coronavirus pneumonia 2019 (COVID-19) is a systemic infectious disease with prominent involvement of the respiratory tract, due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)<sup>[1]</sup>. Systemic lupus erythematosus is charcterized by an aberrant immune response with the presence of circulating autoantibodies, lymphopenia, and proinflammatory<sup>[2]</sup>. They are immune-compromised and vulnerable to infections with immune-suppressants treatment. However, data regarding the impact of COVID-19 pandemic in patients with SLE and drug use were relatively scarce. <h3>Objectives</h3> The prevalence of COVID-19 in SLE patients was estimated by means of meta-analysis, and the effect of the use of anti-rheumatic drugs on the clinical outcome of SLE patients with COVID-19 was investigated. <h3>Methods</h3> Cross-sectional investigations and case series on SLE and COVID-19 published by CBM, CNKI, China Science and Technology Journal Database, Wan Fang Data, PubMed, Embase, Web of Science, Cochrane Library and Medline from its establishment to November 10, 2021 were searched. Random effects model was used to pool data. Heterogeneity and risk of bias was examined with I-squared index (I<sup>2</sup>) statistic. Inconsistency was evaluated by using the I<sup>2</sup>. Egger tests were used for the evaluation of potential publication bias (STATA v.12.0). <h3>Results</h3> A total of 14 studies comprising 5365 patients were identified (Table 1). Overall prevalence of COVID-19 in SLE patients was 1.5% (95%CI: 1.2%-1.8%). Eight of the studies included patients who used hydroxychloroquine as part of their treatment regimen, with 29.8% (95%CI: 25.8%-33.8%) hospitalization rates and 14.6% (95%CI: 11.5%-17.8%) adverse outcome rates. Among patients treated with hydroxychloroquine throughout the course of disease, the prevalence was 0.7% (95%CI: 0.4%-1.0%, Figure 1). <h3>Conclusion</h3> Patients with SLE had a higher risk of COVID-19. Hydroxychloroquine might benefit to reduce the overall hospitalization rate and prevalence rate of COVID-19, and alleviate inflammatory damage in the chronic stage of viral infection by inhibiting over activation of the immune system. <h3>References</h3> [1]SCHULTZE J L, ASCHENBRENNER A C. COVID-19 and the human innate immune system [J]. Cell, 2021, 184(7): 1671-92. [2]KIRIAKIDOU M, CHING C L. Systemic Lupus Erythematosus [J]. Ann Intern Med, 2020, 172(11): Itc81-itc96. <h3>Acknowledgements</h3> This work was supported by the National Natural Science Foundation of China (No. 82001740). <h3>Disclosure of Interests</h3> None declared
Abstract 3885: Adenosine A <sub>2A</sub> and A <sub>2B</sub> Receptors Work in Concert to Produce a Strong Protection against Reperfusion Injury by Targeting the mPTP via a GSK-3β-Dependent Mechanism
Authors: Jinkun Xi, SungRyul Lee, Min Zhu, Rachel McIntosh, Robert A Mueller, Edward A Norfleet, Zhelong Xu
Journal: Circulation (2008)

While the role of adenosine A 2 receptor activation in modulation of reperfusion injury has been extensively investigated, controversies still exist regarding its exact role (protective or not). We aimed to test if a simultaneous stimulation of A 2A and A 2B receptors can produce a strong protection against reperfusion injury by targeting mitochondrial permeability transition pore (mPTP) and glycogen synthase kinase 3β (GSK-3β). NECA (100 nM) given at reperfusion reduced infarct size in isolated rat hearts (14.1 ± 1.9 % vs. 37.9 ± 3.1 % of risk zone in control), an effect that was blocked by both the A 2A antagonist SCH58261 (36.6 ± 2.4 %) and the A 2B antagonist MRS1706 (39.2 ± 2.9 %), indicating that both the receptor subtypes are involved in the anti-infarct effect of NECA. NECA increased GSK-3β phosphorylation at Ser 9 and translocated GSK-3β to mitochondria upon reperfusion, an effect that was blocked by both SCH58261 and MRS1706, implying that NECA may protect the heart at reperfusion by targeting GSK-3β and mitochondria through activation of both A 2A and A 2B receptors. In support of this interpretation, NECA prevented oxidant-induced loss of mitochondrial membrane potential (MMP) in cardiomyocytes (91.2 ± 3.7 % vs. 38.8 ± 5.4 % in control), which was also partially blocked by both SCH58261 and MRS1706, indicating that NECA prevents mPTP opening by stimulating both A 2A and A 2B receptors. Further experiments showed that a combination of CGS21680 (A 2A agonist) and BAY60 – 6583 (A 2B agonist) induced a greater protection against the loss of MMP (84.7 ± 1.1 %) than that induced by CGS21680 (55.6 ± 2.9 %) or BAY60 – 6583 (63.7 ± 5.0) alone, corroborating the above observations. In conclusion, these data suggest that A 2A and A 2B receptors work in concert to prevent reperfusion injury by targeting mPTP through a GSK-3β-dependent mechanism.
Council on Drugs. List No. 107. New names
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Authors: Garret A. FitzGerald
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gene therapy
Authors: W. F. Anderson
Journal: JAMA (1981)

<h3>Can Gene Therapy Help Me?</h3> This article is designed to help the practicing physician answer the patient with a genetic disease who asks, "Can gene therapy help me?" The answer depends on the patient's disease, but for some genetic conditions, gene therapy should be a beneficial therapeutic procedure in the coming years. This brief review examines the present state of the art, points out what still needs to be accomplished before gene therapy will be practical, and concludes by suggesting the potential and the limitations of this promising, but not yet available, technology. Progress in the area of "genetic engineering" has been spectular in recent years. Not only are bacteria being programmed to produce medically useful compounds (insulin, growth hormone, etc), but genes have been transferred into mammalian cells successfully. Individual cells in tissue culture have been cured of genetic defects by insertion of a normal gene.<sup>1-3</sup>Purified genes
Precaution when Using Throat Packs: Correction
Journal: BMJ (1946)

Car Expenses B. R.'s demobilization leave expired on April 3, 1946.He bought a car for £575 on March 28 and began work as an assistant in general practice on June 1.What car allowances can he claim?(It is assumed that lhis agreement requires him to own and use a car at his own expense.)He can claim an " initial allowance " (at 20°%) and " depreciation allowance " (at 25% per annum) for the period from June 1, 1946, to April 5, 1947.Some difficulty may be experienced in determining the amount on which these allowances should be calculated -assuming that the car was used privateiy before June 1.A reasonable basis would seem to be to take the starting figure at £575 less 20% depreciation for two months-i.e., £575-(2/12 of 115 of £575)=£556.The usual rurming costs, etc.
Biological Monitoring of Workers Exposed to N-Nitrosodiethanolamine in the Metal Industry
Authors: Silvano Monarca, Giuseppina Scassellati-Sforzolini, Francesco Donato, Giuseppe Angeli, Berthold Spiegelhalder, Cristina Fatigoni, Rossana Pasquini
Journal: Environmental Health Perspectives (1996)

Biological monitoring of occupational hazards was performed in workers using cutting fluids containing N-nitrosodiethanolamine (NDELA). The study involved a group of 25 male subjects from some metal factories in central Italy who used cutting fluids with an NDELA content of > or = 5 mg/l (high-exposure group) and a group of 37 males exposed to cutting fluids with an NDELA content < 5 mg/l (low-exposure group). For comparison, we recruited a control group consisting of 37 subjects living in the same area. For all subjects, internal dose (urinary excretion of NDELA, mutagens, and thioethers), early biological effects (sister chromatid exchanges in blood peripheral lymphocytes), and urinary excretion of D-glucaric acid (DGA) as an endpoint product in the glucuronidation pathway were assessed. The results showed that only the workers using cutting fluids with NDELA concentrations of > or = 5 mg/l excreted trace amounts of NDELA in their urine. Urine excretion of mutagens was similar in the two exposure groups and in the controls. High-exposure subjects had a higher mean value of urinary thioethers than low-exposure and control subjects, but no differences were found in urinary DGA or lymphocyte sister chromatid exchange among the three groups. Smoking status increased the mean values of all the biomarkers, and coffee drinking was associated with urinary DGA excretion.
Irresponsibility of Criminal with Latent Epilepsy.—
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
National Cancer Institute Monograph No. 9
Journal: JNCI Journal of the National Cancer Institute (1962)

Journal Article National Cancer Institute Monograph No. 9 Get access JNCI: Journal of the National Cancer Institute, Volume 29, Issue 1, July 1962, Page 226, https://doi.org/10.1093/jnci/29.1.226 Published: 01 July 1962
Abstract 484: Large Tumor Suppressor 2, A Downstream Target of Mammalian Sterile 20 Like Kinase 1, Is an Endogenous Regulator of Myocyte Size and Apoptosis in the Heart
Authors: Yutaka Matsui, Noritsugu Nakano, Hiromitsu Takagi, Dan Shao, Shumin Gao, Chull Hong, Peiyong Zhai, Norikazu Yabuta, Hiroshi Nojima
Journal: Circulation (2008)

Mammalian sterile 20-like kinase 1 (Mst1) plays an important role in mediating apoptosis and inhibiting hypertrophy in the heart. Mst1 forms a complex with hWW45 and Large tumor suppressor 2 (Lats2), thereby activating Lats2. Lats2 dose dependently increased apoptosis in cultured cardiac myocytes and transgenic mice with cardiac specific expression of Lats2 exhibited a cardiac dysfunction, suggesting that stimulation of Lats2 leads to increased cell death and cardiac dysfunction. In order to elucidate the function of endogenous Lats2 in the heart, we generated adenovirus harboring dominant-negative Lats2 (Ad-DN-Lats2) and transgenic mice with cardiac specific expression of dominant-negative Lats2 (Tg-DN-Lats2). Ad-DN-Lats2 prevented induction of apoptosis and inhibition of hypertrophy by Mst1 in cultured cardiac myocytes, suggesting that Lats2 mediates the function of Mst1. In Tg-DN-Lats2, both LV weight/tibia length (LVW/TL; 4.34 vs 3.68, N=9, N=7, p&lt;0.01) and RV weight/tibia length (1.15 vs 0.88, N=9, N=7, p&lt;0.01) were greater than in NTg. Echocardiographically determined LV function was normal in Tg-DN-Lats2 at baseline except that LV wall thickness was greater in Tg-DN-Lats2 than in NTg (LV posterior wall thickness; 0.97 vs 0.79 mm, N=10, N=7, p&lt;0.05). Since expression of Lats2 is increased in response to pressure overload (8 fold), we examined whether upregulation of endogenous Lats2 during pressure overload works as a negative feedback mechanism for cardiac hypertrophy. Tg-DN-Lats2 mice exhibited greater LVW/TL than NTg after transverse aortic constriction (TAC) (5.9 vs 4.7 mm, N=9, N=7, p&lt;0.05). Increases in LVW/TL (+37% vs 27%, N=9, N=7, p&lt;0.05) and LV cross sectional area (+25% vs +16%, N=5, N=5, p&lt;0.05) after TAC were greater in Tg-DN-Lats2 than those in NTg. Moreover, Tg-DN-Lats2 exhibited significantly lower cardiac myocyte apoptosis than NTg after TAC. These results suggest that Lats2 is a negative regulator of cardiac hypertrophy at baseline and in response to pressure overload, and a positive mediator of cardiac myocyte apoptosis under pressure overload. In conclusion, Lats2 is an evolutionarily conserved negative regulator of organ size: namely inhibiting hypertrophy while stimulating apoptosis in the heart. This research has received full or partial funding support from the American Heart Association, AHA Founders Affiliate (Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island, Vermont).
Outbreak of Pneumococcal Pneumonia Among Unvaccinated Residents of a Nursing Home—New Jersey, April 2001
Journal: JAMA (2001)

On April 24,2001, seven cases of pneumococcal pneumonia with bacteremia among residents of a nursing home were reported to the Hamilton Township Department of Health, New Jersey; all seven diagnoses were confirmed with blood cultures positive for Streptococcus pneumoniae. Illness onset among the residents occurred during April 3-24; four residents died. The New Jersey Department of Health and Senior Services (NJDHSS) was notified on April 24 and initiated an investigation to identify additional cases and implement control efforts. This report summarizes results of the investigation, which underscore the importance of providing pneumococcal polysaccharide vaccine (PPV) to elderly residents of long-term care facilities (LTCFs).
Aberrant Transcriptional Regulation of the MLL Fusion Partner EEN Gene by AML1-ETO and Its Implication in Leukemogenesis.
Authors: Li-Heng Ma, Han Liu, Hui Xiong, Bing Chen, Yi Fang, Xiao-Mei Zhang, Yue-Ying Wang, Qiu-Hua Huang, Qing-Hua Zhang, Bo-Liang Li, Zhu Chen, Sai-Juan Chen
Journal: Blood (2006)
SAWDUST DERMATITIS
Authors: Oscar L. Levin
Journal: JAMA (1933)

During the past three decades, the specialty of dermatology has grown increasingly comprehensive. In fact, the subject of dermatitis has grown to considerable economic importance since the introduction of compensation laws. In a dermatologic case recently referred to me, I found that a dermatitis of the hands and forearms resulted from the handling of sawdust. The occurrence of dermatitis venenata from contact with plants and wood has been known for many years. It is less well known, however, that so apparently innocuous a substance as sawdust contains chemicals that may arouse a disabling occupational disease. The literature contains rather meager references to this subject. It is my purpose in this paper to record an illustrative case. <h3>REPORT OF CASE</h3><h3>History.</h3> —A. S., a married woman, aged 50, a sweeper in a department store, referred to me, Aug. 13, 1931, complained of an intensely itchy eruption of both hands of seven